Mirtazapin Actavis (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine, and by antagonizing 5‑HT2 and 5‑HT3 receptors while sparing 5‑HT1A. This dual action boosts both norepinephrine and serotonin signaling, contributing to its antidepressant effect.

The appropriate dose of Mirtazapin Actavis is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional guidelines and patient-specific factors.

Safety data for mirtazapine in pregnancy and lactation are limited. The prescriber should weigh potential benefits against possible risks and consider alternative treatments if safety cannot be assured. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss options with their healthcare provider.

To request Mirtazapin Actavis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapin Actavis (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined α2‑adrenergic blockade and 5‑HT2/5‑HT3 antagonism. This profile often results in pronounced sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtazapin Actavis should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date.

Mirtazapin Actavis is taken orally, usually once daily in the evening because of its sedative effect. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for suicidal thoughts or behaviors, especially when treatment is initiated or dosage is changed, as well as rare but severe reactions such as agranulocytosis, seizures, and significant hepatic injury. Patients should be monitored closely for any new or worsening symptoms.

Mirtazapin Actavis is contraindicated in patients who have taken a monoamine oxidase inhibitor within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder, as it may precipitate mania.